Søgeord (influenza) valgt.
17 emner vises.
1
Digital Nudges Found to Be Duds in Flu Vax Trial
Medscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Reminders sent via text message or patient portal did not increase rates of influenza vaccination. Medscape Medical News
Læs mere
2
Communicable disease threats report, 24-30 March 2024, week 13
ECDC
ECDC Communicable Disease Threats Report, 27.03.2024
Tilføjet 27.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 24-30 March 2024 and includes updates on cholera and influenza A(H5N1).
Læs mere
3
Severe Flu Confers Higher Risk for Neuro Disorders vs COVID
Medscape Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Hospitalization for influenza raises the risk for future neurologic conditions more than hospitalization for COVID-19, the results of a large study showed. Medscape Medical News
Læs mere
4
Reporting Protocol for integrated respiratory virus surveillance, version 1.5
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
5
Communicable disease threats report, 10-16 March 2024, week 11
ECDC
ECDC COVID-19 updates, 15.03.2024
Tilføjet 15.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
Læs mere
6
Communicable disease threats report, 10-16 March 2024, week 11
ECDC
ECDC Communicable Disease Threats Report, 15.03.2024
Tilføjet 15.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
Læs mere
7
Communicable disease threats report, 25 February - 2 March 2024, week 9
ECDC
ECDC COVID-19 updates, 2.03.2024
Tilføjet 2.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
8
Communicable disease threats report, 25 February - 2 March 2024, week 9
ECDC
ECDC Communicable Disease Threats Report, 1.03.2024
Tilføjet 1.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
9
Does an October Birthday Protect Kids From Flu?
Medscape Infectious Diseases, 1.03.2024
Tilføjet 1.03.2024
New research showed that children born in October may have lower rates of influenza diagnosis. Medscape Medical News
Læs mere
10
Effectiveness of interventions to increase healthcare workers’ adherence to vaccination against vaccine-preventable diseases: a systematic review and meta-analysis, 1993 to 2022
Marco Clari, Beatrice Albanesi, Rosanna Irene Comoretto, Alessio Conti, Erika Renzi, Michela Luciani, Davide Ausili, Azzurra Massimi and Valerio Dimonte
Eurosurveillance latest updates, 1.03.2024
Tilføjet 1.03.2024
BackgroundVaccination adherence among healthcare workers (HCWs) is fundamental for the prevention of vaccine-preventable diseases (VPDs) in healthcare. This safeguards HCWs\' well-being, prevents transmission of infections to vulnerable patients and contributes to public health. AimThis systematic review and meta-analysis aimed to describe interventions meant to increase HCWs’ adherence to vaccination and estimate the effectiveness of these interventions. MethodsWe searched literature in eight databases and performed manual searches in relevant journals and the reference lists of retrieved articles. The study population included any HCW with potential occupational exposure to VPDs. We included experimental and quasi-experimental studies presenting interventions aimed at increasing HCWs’ adherence to vaccination against VPDs. The post-intervention vaccination adherence rate was set as the main outcome. We included the effect of interventions in the random-effects and subgroup meta-analyses. ResultsThe systematic review considered 48 studies on influenza and Tdap vaccination from database and manual searches, and 43 were meta-analysed. A statistically significant, positive effect was seen in multi-component interventions in randomised controlled trials (relative risk (RR) = 1.37; 95% CI: 1.13–1.66) and in observational studies (RR = 1.43; 95% CI: 1.29–1.58). Vaccination adherence rate was higher in community care facilities (RR = 1.58; 95% CI: 1.49–1.68) than in hospitals (RR = 1.24; 95% CI: 0.76-2.05). ConclusionInterventions aimed at increasing HCWs’ adherence to vaccination against VPDs are effective, especially multi-component ones. Future research should determine the most effective framework of interventions for each setting, using appropriate study design for their evaluation, and should compare intervention components to understand their contribution to the effectiveness.
Læs mere
11
Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 29.02.2024
Tilføjet 29.02.2024
This report describes estimated vaccine effectiveness for laboratory-confirmed flu in California.
Læs mere
12
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States
Morbidity and Mortality Weekly Report (MMWR), 29.02.2024
Tilføjet 29.02.2024
This report describes estimates of 2023-24 influenza vaccine effectiveness among different age groups.
Læs mere
13
Communicable disease threats report, 18-24 February 2024, week 8
ECDC
ECDC COVID-19 updates, 24.02.2024
Tilføjet 24.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
14
Communicable disease threats report, 18-24 February 2024, week 8
ECDC
ECDC Communicable Disease Threats Report, 23.02.2024
Tilføjet 23.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
15
Europe Greenlights Two Avian Flu Vaccines
Medscape Infectious Diseases, 23.02.2024
Tilføjet 23.02.2024
The vaccines, Celldemic and Incellipan, protect against the H5N1 subtype of the influenza A virus. Medscape Medical News
Læs mere
16
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
Hannah Chung, Michael A Campitelli, Sarah A Buchan, Aaron Campigotto, Natasha S Crowcroft, Jonathan B Gubbay, James KH Jung, Timothy Karnauchow, Kevin Katz, Allison J McGeer, J Dayre McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Margaret L Russell, Kevin L Schwartz, Andrew Simor, Marek Smieja, Maria E Sundaram, Bryna F Warshawsky, George Zahariadis, Jeffrey C Kwong and on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWaning immunity from seasonal influenza vaccination can cause suboptimal protection during peak influenza activity. However, vaccine effectiveness studies assessing waning immunity using vaccinated and unvaccinated individuals are subject to biases. AimWe examined the association between time since vaccination and laboratory-confirmed influenza to assess the change in influenza vaccine protection over time. MethodsUsing linked laboratory and health administrative databases in Ontario, Canada, we identified community-dwelling individuals aged ≥ 6 months who received an influenza vaccine before being tested for influenza by RT-PCR during the 2010/11 to 2018/19 influenza seasons. We estimated the adjusted odds ratio (aOR) for laboratory-confirmed influenza by time since vaccination (categorised into intervals) and for every 28 days. ResultsThere were 53,065 individuals who were vaccinated before testing for influenza, with 10,264 (19%) influenza-positive cases. The odds of influenza increased from 1.05 (95% CI: 0.91–1.22) at 42–69 days after vaccination and peaked at 1.27 (95% CI: 1.04–1.55) at 126–153 days when compared with the reference interval (14–41 days). This corresponded to 1.09-times increased odds of influenza every 28 days (aOR = 1.09; 95% CI: 1.04–1.15). Individuals aged 18–64 years showed the greatest decline in protection against influenza A(H1N1) (aORper 28 days = 1.26; 95% CI: 0.97–1.64), whereas for individuals aged ≥ 65 years, it was against influenza A(H3N2) (aORper 28 days = 1.20; 95% CI: 1.08–1.33). We did not observe evidence of waning vaccine protection for individuals aged
Læs mere
17
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria Pérez-Gimeno, Silke Buda, Noémie Sève, Adele McKenna, Adam Meijer, Ana Paula Rodrigues, Iván Martínez-Baz, Ivan Mlinarić, Neus Latorre-Margalef, Gergő Túri, Mihaela Lazăr, Clara Mazagatos, Aitziber Echeverria, Stephen Abela, Marc Bourgeois, Ausenda Machado, Ralf Dürrwald, Goranka Petrović, Beatrix Oroszi, Ligita Jancoriene, Alexandru Marin, Petr Husa, Roisin Duffy, Frederika Dijkstra, Virtudes Gallardo García, Luise Goerlitz, Vincent Enouf, Charlene Bennett, Mariëtte Hooiveld, Raquel Guiomar, Camino Trobajo-Sanmartín, Vesna Višekruna Vučina, Tove Samuelsson Hagey, Ana Sofía Lameiras Azevedo, Jesús Castilla, Gerd Xuereb, Bénédicte Delaere, Verónica Gómez, Kristin Tolksdorf, Sabrina Bacci, Nathalie Nicolay, Marlena Kaczmarek, Angela MC Rose and on behalf of the European IVE group
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
Læs mere